Luye Pharma Group Ltd.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a LYPHF research report →
About the company
Luye Pharma Group Ltd. , serving as an investment holding company, engages in the global research, development, production, commercialization, and distribution of a diverse portfolio of pharmaceutical products. Their oncology treatments include Lipusu, indicated for ovarian and breast cancer; CMNa, a chemical sensitizer used in cancer radiotherapy; Tiandida, targeting ovarian or non-small cell lung cancer; and Boyounuo, an injection addressing various cancers and solid tumors.
- CEO
- Dian Bo Liu
- IPO
- 2021
- Employees
- 5,150
- HQ
- Yantai, CN
Price Chart
- Market Cap
- $815.28M
- P/E
- 11.41
- P/S
- 1.11
- P/B
- 0.44
- EV/EBITDA
- 6.33
- Div Yield
- 0.00%
- Gross Margin
- 65.99%
- Op Margin
- 19.70%
- Net Margin
- 9.81%
- ROE
- 4.02%
- ROIC
- 3.13%
- Revenue
- $6.15B · 1.39%
- Net Income
- $602.78M · 27.74%
- EPS
- $0.15 · 757.14%
- Op Income
- $1.22B
- FCF YoY
- 150.65%
- 52W High
- $0.40
- 52W Low
- $0.20
- 50D MA
- $0.29
- 200D MA
- $0.34
- Beta
- 0.86
- Avg Volume
- 66.13K
Get TickerSpark's AI analysis on LYPHF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our LYPHF coverage
Recent articles, reports, and earnings notes.
No research on LYPHF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate LYPHF report →Similar companies
Peers in the same neighborhood.